Abstract
Five new drugs marketed within the last year that are used for medical problems often experienced by the elderly have been selected for consideration in this review. The uses and most important properties of these agents are discussed, and a rating for each new drug is determined using the New Drug Comparison Rating system developed by the author (DAH). Advantages, disadvantages, and other important information regarding each new drug are identified and used as the basis for determining the rating. The drugs include two antidiabetic agents, an agent for gout, an antipsychotic agent, and a drug for dry eye disease.
MeSH terms
-
Anti-Inflammatory Agents / adverse effects
-
Anti-Inflammatory Agents / therapeutic use*
-
Antipsychotic Agents / adverse effects
-
Antipsychotic Agents / therapeutic use*
-
Drugs, Investigational / adverse effects
-
Drugs, Investigational / therapeutic use*
-
Dry Eye Syndromes / drug therapy
-
Gout Suppressants / adverse effects
-
Gout Suppressants / therapeutic use*
-
Humans
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / therapeutic use*
-
Insulin, Long-Acting / therapeutic use
-
Peptides / therapeutic use
-
Phenylalanine / analogs & derivatives
-
Phenylalanine / therapeutic use
-
Piperidines / therapeutic use
-
Sulfones / therapeutic use
-
Thioglycolates / therapeutic use
-
Triazoles / therapeutic use
-
Urea / analogs & derivatives
-
Urea / therapeutic use
Substances
-
Anti-Inflammatory Agents
-
Antipsychotic Agents
-
Drugs, Investigational
-
Gout Suppressants
-
Hypoglycemic Agents
-
Insulin, Long-Acting
-
Peptides
-
Piperidines
-
Sulfones
-
Thioglycolates
-
Triazoles
-
lifitegrast
-
lesinurad
-
Phenylalanine
-
insulin degludec
-
lixisenatide
-
Urea
-
pimavanserin